ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.29, Bloomberg Earnings reports. The firm had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $3.52 million.

Shares of ADMA Biologics (ADMA) traded up 1.03% during mid-day trading on Friday, hitting $2.94. 36,784 shares of the stock traded hands. The stock’s market cap is $37.88 million. The firm has a 50 day moving average of $3.47 and a 200 day moving average of $4.19. ADMA Biologics has a 12 month low of $2.76 and a 12 month high of $7.70.

Several analysts have recently commented on ADMA shares. Maxim Group set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Monday, May 15th. ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Earnings History for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.